NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Frontier Medicines

Frontier Medicines

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.frontiermeds.com/

Last Round

Series C

Feb 22, 2024

Total Funding Raised

$255.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Frontier Medicines is a clinical-stage biopharmaceutical company that develops precision medicines for genetically-defined patient populations by utilizing a proprietary chemoproteomics and machine learning platform to target previously 'undruggable' proteins.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Precision Medicine, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoveryprecision medicinesmall molecule therapeuticscovalent inhibitorschemoproteomicsundruggable targetsai drug discoverybiotechoncology therapeuticsin silico drug designprotein binding sitespharma partnershipscomputational biologycovalent chemistryai-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Frontier Medicines Comparables

Compare Frontier Medicines with similar companies based on industry and business-model similarity.

Frontier Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genesis Molecular AI
85%
Iambic Therapeutics
85%
Antares Therapeutics
85%

Frontier Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CFeb 22, 2024
Series BJul 19, 2021
Series AJun 25, 2019

Key People

Founding team and executive leadership

Chris Varma

Co-Founder, Chairman CEO

Founding Team

Johannes Hermann

Chief Technology Officer

Executive Team

Gerardo Ubaghs Carrión

Chief Financial Officer

Executive Team

Frontier Medicines Investors

Notable investors and investment history

Frontier Medicines investors
InvestorRounds
Deerfield ManagementSeries B, Series C, Series A
MPM CapitalSeries C, Series B, Series A
RA Capital ManagementSeries C, Series A, Series B
DCVC BioSeries C, Series A
Deep Track CapitalSeries C, Series B
MPM BioImpactSeries C, Series B, Series A
Droia VenturesSeries B, Series C, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 31, 2026

    Partnered with LG Chem for FMC-220, a p53 activator.

  • Mar 17, 2026

    Launched the AI-powered Frontier Platform at AACR Annual Meeting 2026.

Frontier Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Frontier Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Frontier Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range77
Year Founded2018
Last FundingFeb 22, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.